Walter Public Investments Inc. Sells 38,718 Shares of Johnson & Johnson $JNJ

Posted by Brenda Bartman on Nov 12th, 2026

Walter Public Investments Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 57.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 28,216 shares of the company’s stock after selling 38,718 shares during the quarter. Johnson & Johnson makes up approximately 1.8% of Walter Public Investments Inc.’s investment portfolio, making the stock its 23rd biggest position. Walter Public Investments Inc.’s holdings in Johnson & Johnson were worth $7,470,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Outlook Capital Management LLC purchased a new stake in Johnson & Johnson in the second quarter worth about $28,000. Navigoe LLC raised its stake in shares of Johnson & Johnson by 60.4% in the third quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after buying an additional 55 shares during the period. Matrix Trust Co lifted its position in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares in the last quarter. Montgomery Financial Services LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $43,000. Finally, Hanseatic Management Services Inc. bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at approximately $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by insiders.

Top Johnson & Johnson Stories

Here are a few of the latest stories about JNJ:

Positive Sentiment: J&J reported that a second pivotal Phase 3 trial of CAPLYTA met its primary and key secondary endpoints for bipolar I mania, with symptom improvement seen as early as Day 3. The two positive trials support a planned U.S. FDA submission, adding a potential growth opportunity. Reuters article
Positive Sentiment: Oncology sales rose 16.8% to $22 billion in the first nine months of 2026, supported by established medicines and new launches. Another article points to recent launches and business changes as potential support for double-digit growth by 2030, though that outlook is prospective. Oncology sales article
Neutral Sentiment: J&J shares have risen substantially in recent years, prompting questions about whether expected cash flows justify the valuation; this could limit further gains if expectations are already reflected in the stock. Separately, a State Street health-care ETF sold J&J shares while reducing all of its holdings, which does not appear to be a company-specific signal. Valuation article

Johnson & Johnson Price Performance

NYSE:JNJ opened at $280.52 on Thursday. The business’s 50-day simple moving average is $266.67 and its two-hundred day simple moving average is $249.23. Johnson & Johnson has a 52 week low of $193.07 and a 52 week high of $283.25. The stock has a market cap of $675.29 billion, a PE ratio of 42.50, a P/E/G ratio of 2.78 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on JNJ. Royal Bank Of Canada reduced their target price on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. HSBC raised their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. Bank of America reiterated a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

View Our Latest Report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.